IL4I1 and diffuse large B-cell lymphoma: Further analysis of GSE93984 (Figure 3F,G) showed that IL4I1 levels were low in non-responders (n = 64) that received ibrutinib phase II PCYC-1106 trial (NCT01325701) [26], suggesting IL4I1 can modulate ibrutinib resistance in ABC-DLBCL.